Trials / Completed
CompletedNCT01365221
The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
SWITCH 600/60: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Medstar Health Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare platelet reactivity between patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.
Detailed description
This is a prospective, open-label, non-randomized trial of approximately 260 patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In order to compare platelet reactivity, as assessed by the VerifyNow P2Y12 assay, we plan to recruit two study groups of interest: 1. Patients who have already received a 600 mg loading dose (LD) of clopidogrel in preparation for PCI will receive a loading dose of 60 mg of prasugrel. 2. Patients who have not received a LD of clopidogrel will receive a 60 mg LD of prasugrel prior to PCI. A subset of 40 patients from each study group (80 patients total) will undergo additional platelet reactivity testing with the vasodilator stimulated phosphoprotein (VASP) assay.All patients will be followed throughout the duration of the hospital stay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prasugrel | Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel |
| DRUG | Prasugrel | Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2011-06-03
- Last updated
- 2020-09-09
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01365221. Inclusion in this directory is not an endorsement.